Critical Care Updates on Long-Term Cellular Therapy Considerations During Critical Illness

Abstract

Cellular therapies, including hematopoietic stem cell transplantation and emerging engineered cell products, are increasingly utilized in a range of malignant and non-malignant disorders, often in patients experiencing or at risk for critical illness. The intersection of critical care and long-term cellular therapy presents unique challenges, including heightened risk for organ dysfunction, infectious complications, and immune-mediated sequelae. This review synthesizes current literature, focusing on the epidemiology, pathophysiology, risk factors, clinical features, diagnostic approaches, management strategies, and recent advances relevant to the critical care of patients undergoing or recovering from cellular therapies. Guideline-based recommendations and expert consensus are discussed to inform best practices and highlight areas for future research.

Introduction

The increasing application of cellular therapies such as hematopoietic stem cell transplantation (HSCT), chimeric antigen receptor (CAR) T-cell therapy, and mesenchymal stromal cell infusions has transformed the management of various hematologic malignancies and immune disorders. As survival rates improve, a growing cohort of patients present to intensive care units (ICUs) with complications related to their underlying disease, cellular therapies, or both. These patients require multidisciplinary, nuanced approaches to care due to their complex immune status, risk of multiorgan dysfunction, and exposure to novel immunomodulatory agents. Understanding the evolving landscape of critical illness in the setting of long-term cellular therapy is essential for optimizing outcomes.

Epidemiology / Disease Burden

Recent epidemiological data indicate that up to 40% of patients undergoing allogeneic HSCT will require ICU admission within the first year post-transplant, with mortality rates in the ICU setting historically exceeding 50%. The increasing use of CAR T-cell therapies and other adoptive cell transfers has introduced new patterns of critical illness, such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). These complications are seen in up to 60-80% of CAR T-cell recipients, with varying severity. Infectious complications, graft-versus-host disease (GVHD), and organ toxicities remain major drivers of morbidity and mortality in this population, underscoring the need for updated critical care strategies.

Pathophysiology

Critical illness in recipients of cellular therapies is multifactorial. Immune dysregulation, driven by conditioning regimens, cellular grafts, and subsequent immunosuppression, underlies many complications. CRS, a hallmark of CAR T-cell therapy, results from rapid immune activation and massive cytokine release, leading to capillary leak, hypotension, and multiorgan failure. GVHD involves alloimmune activation against recipient tissues, affecting the skin, gut, and liver. The disruption of mucosal barriers and neutropenia predispose patients to severe infections. Endothelial injury, microangiopathy, and complement activation also contribute to organ dysfunction and thrombotic complications in this context.

Risk Factors

Risk factors for critical illness include the type and intensity of conditioning regimens, degree of HLA mismatch, pre-existing comorbidities, and the specific cellular therapy used. Allogeneic HSCT, especially with unrelated or mismatched donors, confers higher risk of severe GVHD and infections. CAR T-cell therapies targeting CD19 are associated with higher rates of severe CRS in patients with high disease burden or elevated baseline inflammatory markers. Advanced age, pre-transplant organ dysfunction, and prior infectious exposures further increase susceptibility to adverse outcomes during critical illness.

Clinical Features

Clinical manifestations in this population are heterogeneous. CRS typically presents with fever, hypotension, hypoxemia, and, in severe cases, shock and multiorgan dysfunction. ICANS may manifest as confusion, aphasia, seizures, or cerebral edema. GVHD presents with rash, diarrhea, jaundice, and transaminitis. Infectious complications can include bacterial sepsis, viral reactivation (e.g., CMV, EBV), and invasive fungal diseases. Other features include acute kidney injury, respiratory failure, and coagulopathy, necessitating vigilant monitoring and rapid intervention.

Diagnosis

Diagnosis relies on clinical assessment supported by laboratory markers (e.g., ferritin, CRP, IL-6), imaging, and tissue biopsies when indicated. Grading systems for CRS and ICANS, such as the ASTCT consensus criteria, aid in stratifying severity and guiding management. Microbiological workup should be prompt and comprehensive, given the high risk of atypical and multidrug-resistant infections. Diagnostic evaluation for GVHD includes skin, gut, or liver biopsies, with ancillary tests such as stool PCR for infectious differential diagnoses. Echocardiography and pulmonary imaging are essential in evaluating organ dysfunction.

Treatment & Management

Management strategies are multidisciplinary and must be tailored to the underlying complication. Supportive care remains the cornerstone, including hemodynamic stabilization, organ support (mechanical ventilation, renal replacement therapy), and meticulous infection control. CRS is managed with anti-IL-6 therapies (tocilizumab) and corticosteroids for severe cases. ICANS may require high-dose steroids and anti-seizure prophylaxis. GVHD management includes immunosuppressants (calcineurin inhibitors, methotrexate) and novel agents such as JAK inhibitors. Infection management is guided by local epidemiology and antimicrobial stewardship principles. Early involvement of transplant, infectious disease, and critical care specialists is essential.

Recent Advances / Emerging Therapies

Recent advances include the development of more precise grading tools for CRS and ICANS, allowing for earlier and more targeted interventions. Novel cellular therapies with improved safety profiles, such as armored CAR T-cells and suicide gene-modified products, are under investigation. Biomarker-driven risk stratification and personalized immunosuppression protocols are being explored to minimize toxicity. Advances in antifungal prophylaxis, viral monitoring, and rapid diagnostic techniques have improved infectious outcomes. Ongoing trials are evaluating agents targeting specific cytokine pathways, endothelial protection strategies, and innovative supportive care modalities.

Guideline Recommendations

Current guidelines from organizations such as the American Society for Transplantation and Cellular Therapy (ASTCT) and the European Society for Blood and Marrow Transplantation (EBMT) emphasize early recognition and graded management of CRS and ICANS, infection prophylaxis, and multidisciplinary care. Recommendations underscore the importance of standardized diagnostic criteria, aggressive supportive care, and individualized immunosuppression. Timely ICU admission and the use of validated risk scores can improve triage and outcomes. Clinical pathways should be regularly updated to incorporate emerging evidence and novel therapies.

Conclusion

The management of critically ill patients receiving long-term cellular therapies is rapidly evolving, necessitating the integration of hematologic, immunologic, and critical care expertise. Ongoing research is refining our understanding of the pathophysiology and optimal management of complications such as CRS, ICANS, GVHD, and infection. Adherence to evidence-based guidelines, multidisciplinary collaboration, and early intervention remain essential to improving outcomes. Future directions include precision medicine approaches, novel therapeutics, and enhanced supportive care strategies tailored to this vulnerable population.